Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 25(2)2024 Jan 19.
Article in English | MEDLINE | ID: mdl-38279244

ABSTRACT

Infective endocarditis (IE) remains a dangerous disease and continues to have a high mortality rate. Unfortunately, despite continuous improvements in diagnostic methods, in many cases, blood cultures remain negative, and the pathogen causing endocarditis is unknown. This makes targeted therapy and the selection of appropriate antibiotics impossible. Therefore, we present what methods can be used to identify the pathogen in infective endocarditis. These are mainly molecular methods, including PCR and MGS, as well as imaging methods using radiotracers, which offer more possibilities for diagnosing IE. However, they are still not widely used in the diagnosis of IE. The article summarizes in which cases we should choose them and what we are most hopeful about in further research into the diagnosis of IE. In addition, registered clinical trials that are currently underway for the diagnosis of IE are also presented.


Subject(s)
Endocarditis, Bacterial , Endocarditis , Humans , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Endocarditis/diagnostic imaging , Anti-Bacterial Agents/therapeutic use
2.
Curr Probl Cardiol ; 49(1 Pt C): 102127, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37802171

ABSTRACT

Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic kidney disease, arterial hypertension and type 2 diabetes mellitus. Subsequently, thromboembolic risk stratification in this population poses a great challenge. Since date from the large randomized clinical trials mostly include both patients with truly preserved EF, and those with heart failure with mildly reduced ejection fraction, there is an unmet need to characterize the patients with truly preserved EF. Considering the significant evidence gap in this area, we sought to describe the coagulation disorders and thrombotic complications in patients with HFpEF and discuss the specific thromboembolic risk factors in patients with HFpEF, with the goal to tailor risk stratification to an individual patient.


Subject(s)
Blood Coagulation Disorders , Diabetes Mellitus, Type 2 , Heart Failure , Thromboembolism , Thrombosis , Humans , Heart Failure/epidemiology , Heart Failure/etiology , Heart Failure/drug therapy , Stroke Volume , Diabetes Mellitus, Type 2/epidemiology , Comorbidity , Thrombosis/epidemiology , Thrombosis/etiology , Blood Coagulation Disorders/epidemiology , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...